干扰素λ4基因型对丙型肝炎直接抗病毒治疗期间干扰素刺激基因表达的影响
研究探讨丙型肝炎直接抗病毒治疗中干扰素λ4(IFNL4)基因型与干扰素刺激基因(ISG)表达的关系。在BOSON试验中,基因3型合并肝硬化患者接受索非布韦联合利巴韦林16周治疗,持续病毒学应答率约50%;IFNL4 CC基因型与持续病毒学应答显著相关,且基线外周血和肝内ISG特征较低。CC基因型患者在治疗第4至16周ISG表达动态升高,非CC基因型则相反。
要点
- IFNL4 CC基因型与肝硬化患者持续病毒学应答显著相关。
- CC基因型基线外周血和肝内ISG特征较低。
- CC基因型治疗第4至16周ISG表达升高,非CC基因型相反。
核心结论
- 这些数据提供了丙型肝炎治疗中宿主基因型与表型之间重要的动态联系,也可能与自然获得性感染相关。
研究设计与样本
- 基于BOSON试验的分析,纳入基因3型合并肝硬化且接受索非布韦联合利巴韦林16周治疗的患者。
主要发现
- 基因3型合并肝硬化患者接受索非布韦联合利巴韦林16周治疗,持续病毒学应答率约50%。
- 肝硬化患者中IFNL4 CC基因型与持续病毒学应答显著相关。
- CC基因型与基线外周血和肝内较低的ISG特征相关。
- CC基因型患者在治疗第4至16周ISG表达动态升高,非CC基因型则相反。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
New directly acting antivirals (DAAs) provide very high cure rates in most patients infected by hepatitis C virus (HCV). However, some patient groups have been relatively harder to treat, including those with cirrhosis or infected with HCV genotype 3. In the recent BOSON trial, genotype 3, patients with cirrhosis receiving a 16-week course of sofosbuvir and ribavirin had a sustained virological response (SVR) rate of around 50%. In patients with cirrhosis, interferon lambda 4 (IFNL4) CC genotype was significantly associated with SVR. This genotype was also associated with a lower interferon-stimulated gene (ISG) signature in peripheral blood and in liver at baseline. Unexpectedly, patients with the CC genotype showed a dynamic increase in ISG expression between weeks 4 and 16 of DAA therapy, whereas the reverse was true for non-CC patients. Conclusion: These data provide an important dynamic link between host genotype and phenotype in HCV therapy also potentially relevant to naturally acquired infection. (Hepatology 2018; 00:000-000).
引用
- Ramamurthy N, Marchi E, Ansari MA, et al. Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C. Hepatology. 2018. PMID: 29534310. doi:10.1002/hep.29877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。